Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2004

View Archived Issues

IRA-01 shows fair antiarthritic effect, good safety and favorable lipid profile

SGN-15 and docetaxel combination promising in non-small cell lung cancer

Licofelone in symptomatic OA of the knee

Statins a potential therapeutic option in glaucoma

Vertex scientists prepare and test new inhibitors of JAK, JNK, CDK, etc.

Novel LTD4 antagonists and their use reported by Almirall Prodesfarma

Two series of MEK/c-Src kinase inhibitors claimed by AstraZeneca

New histamine H3 receptor ligands and their use claimed by Abbott

Oral PTH enters phase I trial under Unigene/GSK collaboration

IND accepted for phase II trials of Aplidin

New phase II trial of MDX-070 in hormone refractory prostate cancer

Millennium reacquires Integrilin European rights, licenses to GSK

Target enrollment met in phase III study of Campath for B-CLL

Closing date of Sanofi-Synthelabo's offer on Aventis postponed to July 30, 2004

Phase IIb trial of tgAAVCF for cystic fibrosis cleared to continue

XL-119 enters phase III trial in bile duct cancer

Change of indications for phase II trials of KOS-862

Singapore study for Dynavax HBV prophylactic vaccine

Sigma-Tau plans phase II European trial of TB4 for venous stasis ulcers

RI-624 enters phase I testing for pain

Positive interim results from phase I study of Davanat-1

Antiinflammatory and cardiovascular benefits found with atorvastatin in rheumatoid arthritis

Add-on therapy with safinamide improves motor function in Parkinson's disease

Therapeutic benefits of adjunctive istradefylline in advanced Parkinson's disease

French team prepares and tests a novel antithrombotic agent

Cyclacel claims new CDK inhibitors for cancer and viral infections

Repinotan study results reported at World Stroke Congress

Study parameters affect preclinical outcomes with neuroprotective agents

Study suggests simvastatin can prevent silent brain infarct

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...